The Development and Impact of Tuberculosis Vaccines

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2006 Feb 25

PMID 16497578

Citations 34

Authors

Douglas Young

Christopher Dye

Affiliations

Soon will be listed here.

Abstract

Vaccination is expected to make a major contribution to the goal of eliminating tuberculosis worldwide by 2050. But developing a new effective vaccine will require innovation in scientific research, a proactive approach to clinical trials of new vaccine candidates, and application of vaccines as part of an integrated approach to disease control.

Citing Articles

A novel multi-component protein vaccine ECP001 containing a protein polypeptide antigen nPstS1 riching in T-cell epitopes showed good immunogenicity and protection in mice.

Yu J, Fan X, Luan X, Wang R, Cao B, Qian C Front Immunol. 2023; 14:1138818.

PMID: 37153610 PMC: 10161251. DOI: 10.3389/fimmu.2023.1138818.

Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung.

Ogongo P, Tezera L, Ardain A, Nhamoyebonde S, Ramsuran D, Singh A J Clin Invest. 2021; 131(10).

PMID: 33848273 PMC: 8121523. DOI: 10.1172/JCI142014.

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: Mycobacterial Growth Inhibition Predicts Outcome of Mycobacterial Infection.

Tanner R, Satti I, Harris S, OShea M, Cizmeci D, OConnor D Front Immunol. 2020; 10:2983.

PMID: 31998295 PMC: 6968127. DOI: 10.3389/fimmu.2019.02983.

STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.

Van Dis E, Sogi K, Rae C, Sivick K, Surh N, Leong M Cell Rep. 2018; 23(5):1435-1447.

PMID: 29719256 PMC: 6003617. DOI: 10.1016/j.celrep.2018.04.003.

Breaking Transmission with Vaccines: The Case of Tuberculosis.

Gonzalo-Asensio J, Aguilo N, Marinova D, Martin C Microbiol Spectr. 2017; 5(4).

PMID: 28710848 PMC: 11687530. DOI: 10.1128/microbiolspec.MTBP-0001-2016.